Down Syndrome Market Insights, Epidemiology and Market Forecast-2028
Some of the key facts of the report
1. The total diagnosed Down Syndrome prevalent population in the 7MM was 545,992 in 2017.
2. It was found that Down Syndrome is most prominent in people of age 0–9 years.
3. The most diagnosed Down Syndrome prevalent cases were recorded in the United States.
1. Down Syndrome market report covers a descriptive overview and comprehensive insight of the Down Syndrome epidemiology and Down Syndrome market in the 7 MM (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Down Syndrome market report provides insights on the current and emerging therapies.
3. Down Syndrome market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Down Syndrome market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Down Syndrome market.
“A slightly higher prevalence of Down Syndrome is found in males than in females.”
The current Down Syndrome treatment targets symptoms but does not target the underlying mechanisms causing the deficits. The treatment includes speech therapy, physical therapy, occupational therapy and special education.
Thus, considering the current unmet needs, many companies are investing in the development of appropriate therapies for Down Syndrome treatment. However, many of the recent clinical trials are poorly controlled, and no controlled clinical studies for Down Syndrome have demonstrated their excellent safety and efficacy. Also, with the rise in prenatal screening tests across the US, the number of babies born with Down Syndrome has significantly decreased.
The current Down Syndrome treatment targets symptoms but does not target the underlying mechanisms causing the deficits. The launch of upcoming therapies will increase the Down Syndrome market size during the forecast period (2020–2030). As per DelveInsight’s analysis, the diagnosed prevalence of Down Syndrome will increase during the furcated period (2020–2030). This rise in diagnosed population, as well as increasing awareness among people, will contribute to the growth of Down Syndrome market.
The launch of the emerging therapies is expected to significantly impact Down Syndrome treatment scenario in the upcoming years:-
Drugs covered
1. Pentylenetetrazole (BTD-001)
2. ACI-24
And many others
The key players in Down Syndrome market are:
1. Balance Therapeutics
2. AC Immune
And many others
Table of contents
1. Report Introduction
2. Down syndrome Market Overview at a Glance
3. Down syndrome Disease Background and Overview
4. Down syndrome Epidemiology and Patient Population
5. Epidemiology of Down Syndrome by Countries (2017–2030)
5.1. United States- Epidemiology (2017–2030)
5.2. EU-5 – Epidemiology (2017–2030)
5.2.1. Assumptions and Rationale
5.2.2. Germany
5.2.3. France
5.2.4. Italy
5.2.5. Spain
5.2.6. United Kingdom
5.3. Japan
6. Current Down syndrome Treatments and Medical Practices
7. Unmet Needs
8. Down syndrome Emerging Therapies
8.1. Pentylenetetrazole (BTD-001): Balance Therapeutics
8.2. ACI-24: AC Immune
9. Down Syndrome: 7 Major Market Analysis
10. The United States Market Outlook
10.1. United States Market Size
11. EU-5 Countries Market Outlook
11.1. Germany Market Size
11.2. France Market Size
11.3. Italy Market Size
11.4. Spain Market Size
11.5. UK Market Size
12. Japan Market Outlook
12.1. Japan Market Size
12. Market Drivers
13. Market Barriers
14. Appendix
15. DelveInsight Capabilities
16. Disclaimer
17. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Contact us:
Shruti Thakur
info@delveinsight.com
+919650213330
SOURCE DelveInsight
Media Contact
Company Name: DelveInsight
Contact Person: Priya Maurya
Email: Send Email
Phone: +919650213330
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/